EMEA-001822-PIP01-15-M01 - paediatric investigation plan
Sofosbuvir
velpatasvir
voxilaprevi
PIPHuman
Gilead Sciences Ireland UC
E-mail: regulatory.pip@gilead.com
Tel. +44 1223897300
P/0006/2020: EMA decision of 6 January 2020 on the acceptance of a modification of an agreed paediatric investigation plan for sofosbuvir / velpatasvir / voxilaprevir (Vosevi), (EMEA-001822-PIP01-15-M01)